March 16, 2026
ELPIB (Brazil) introduces the Plasma Project
Ensuring access to essential medicines derived from human plasma has become a strategic priority for many countries. In Brazil, however, dependence on the international market remains a significant challenge—particularly when it comes to immunoglobulin, one of the most widely used plasma-derived therapies worldwide. The Plasma Project – Brazil was created to stimulate dialogue, raise awareness, and encourage public debate on the importance of national self-sufficiency in the production of plasma-derived medicines.
Led by the patient organisation ELPIB (Brazilian patient organisation dedicated to primary immunodeficiencies), the initiative seeks to inform society about the complex journey that transforms human plasma into life-saving treatments. Because the topic remains relatively under-discussed in the public sphere, the project emphasises education and accessible communication.
Why the Plasma Project Matters
Brazil currently relies entirely on the international market for the supply of immunoglobulin and other plasma-derived medicines. This dependence creates structural vulnerability. During global crises—such as pandemics, supply chain disruptions, or geopolitical conflicts—countries that produce plasma-derived therapies often prioritise their own populations, which can limit exports and compromise access in dependent nations.
Another critical aspect is that the production of immunoglobulin is intrinsically linked to the availability of human plasma. Without plasma donations, these therapies simply cannot exist. Immunoglobulin, in particular, plays a crucial role in the treatment of patients with immune disorders and other conditions requiring antibody replacement or modulation, making it one of the most widely consumed plasma-derived medicines globally.
For these reasons, the Plasma Project emphasises the need for Brazil to develop sustainable strategies that ensure a reliable and resilient supply of these therapies for patients.
Project Structure and Timeline
The Plasma Project is designed as a six-month educational and advocacy initiative running from March to August 2026. Its primary audiences include patients, patient advocates, healthcare professionals, and opinion leaders interested in strengthening Brazil’s health system and pharmaceutical autonomy.
The communication strategy includes the publication of 25 sequential educational posts explaining each stage of the immunoglobulin production chain—from plasma donation and fractionation to final patient access. These materials will be supported by a dedicated landing page, targeted search visibility through Google, and outreach to media and professional networks.
Content distribution will take place through major digital platforms, including Meta (Instagram and Facebook), Google, LinkedIn, and Taboola, ensuring broad visibility among both specialised and general audiences.
Expected Impact
By combining education, digital outreach, and public engagement, the Plasma Project aims to build a stronger foundation for advocacy and evidence-based public policy. Expected outcomes include:
- Increased awareness among patients, healthcare professionals, and the general public
- Greater visibility of the challenges surrounding plasma-derived medicines in Brazil
- Engagement of communities and families affected by conditions requiring immunoglobulin therapy
- Sensitisation of healthcare professionals and opinion leaders
- Exposure of decision-makers to the urgency of strengthening national plasma and fractionation strategies
- Growth of an informed audience base and increased traffic to educational resources
Ultimately, the Plasma Project seeks to contribute to a broader national conversation about access to essential therapies and the importance of building resilient health systems capable of protecting patients even in times of global uncertainty.
